Study analysis · Physiological Reports · 2019
This peptide turned fat mice into fat-burning machines in just 3 days — and it’s not what you think.
A tiny mitochondrial peptide called MOTS-c helped obese mice burn fat better and lower blood sugar by changing key fat molecules in their blood.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at mice that got a special peptide and saw that their blood sugar got better and some chemicals in their blood changed. But it doesn’t prove the peptide caused the change — it just shows they happened together. We can’t say it would work in people.
What’s the bottom line?
Scientists gave a special peptide called MOTS-c to fat mice and found it helped their bodies burn fat more efficiently and lowered blood sugar. It changed levels of certain fats and chemicals in the blood that are linked to diabetes and obesity.
How strong is this study?
The study did a good job measuring many things in the mice’s blood, but they didn’t randomly give the peptide or hide who got it — so we can’t be sure the results weren’t just luck or something else. That makes the results less trustworthy for real-world use.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Study is in mice, not humans; no randomization or blinding reported (classified as unknown, so not RCT); cannot prove MOTS-c causes improved insulin sensitivity in humans.
Key takeaways
- 01
MOTS-c lowered 5 key fat-related chemicals in blood by 14% to 42% (all p<0.05).
- 02
It also reduced gene activity in liver and muscle linked to fat storage.
- 03
Blood sugar dropped significantly (p<0.05).
- 04
Results are from mice, not humans.
- 05
While promising, human relevance is not confirmed.
- 06
The changes are biologically significant in the mouse model but require human trials to assess real-world impact.
Surprising findings
- MOTS-c reduces multiple fat molecules linked to diabetes — not just oneMost treatments target one pathway, but MOTS-c simultaneously lowers 5 different fat-related metabolites across 3 metabolic pathways (sphingolipid, monoacylglycerol, dicarboxylate), which is rare and suggests broad metabolic reprogramming.
- MOTS-c reduces ANGPTL4 — a protein that normally blocks fat burningANGPTL4 is known to inhibit fat breakdown, so reducing it should help fat burning — but it’s not commonly targeted by supplements or drugs. MOTS-c’s ability to do this is unexpected and powerful.
Practical takeaways
Consider lifestyle changes that naturally boost MOTS-c, like exercise or fasting — since MOTS-c is an 'exercise mimetic'.
This study used injections, not oral supplements, and human MOTS-c levels are not yet proven to be modifiable by diet or lifestyle.
medium confidenceMonitor blood sugar and fat markers if you’re managing insulin resistance — MOTS-c targets the same pathways.
MOTS-c is not available as a supplement for humans, and this study was in mice.
low confidenceWhy this study matters
MOTS-c Slashes 5 Key Fat Molecules in 3 Days
In just 3 days, MOTS-c injections reduced 5 specific fat-related chemicals in obese mice: sphingosine 1-phosphate by 14%, palmitoyl sphingomyelin by 23%, 2-oleoylglycerol by 32%, suberate by 40%, and sebacate by 42% — all with p-values under 0.05. These molecules are linked to insulin resistance and type 2 diabetes.
This shows a rapid, measurable impact on metabolic health — something people struggling with weight or blood sugar would find hopeful.
MOTS-c Turns Off Fat-Storing Genes in Muscle and Liver
MOTS-c reduced liver Por mRNA expression by 50% and skeletal muscle ANGPTL4 mRNA expression (both p<0.05). ANGPTL4 normally blocks fat breakdown, so lowering it helps muscles burn fat more efficiently.
It’s not just about burning fat — it’s about reprogramming the body’s fat-handling genes, which could mean long-term metabolic improvements.
Blood Sugar Dropped Significantly in Just 3 Days
Mice treated with MOTS-c had significantly lower blood glucose levels than controls (p<0.05). This suggests MOTS-c could help manage insulin resistance — a key factor in type 2 diabetes.
For people with prediabetes or insulin resistance, this is a direct, measurable benefit that could translate to real-world health improvements.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave a special peptide called MOTS-c to fat mice and found it helped their bodies burn fat more efficiently and lowered blood sugar. It changed levels of certain fats and chemicals in the blood that are linked to diabetes and obesity.
Research results
MOTS-c lowered 5 key fat-related chemicals in blood by 14% to 42% (all p<0.05). It also reduced gene activity in liver and muscle linked to fat storage. Blood sugar dropped significantly (p<0.05).
What this means - more context
Results are from mice, not humans. While promising, human relevance is not confirmed. The changes are biologically significant in the mouse model but require human trials to assess real-world impact.
This study investigates the effects of MOTS-c on plasma metabolites and insulin sensitivity in diet-induced obese mice using an unbiased metabolomics approach.
MOTS-c injection in diet-induced obese mice significantly reduced plasma levels of sphingosine 1-phosphate, palmitoyl sphingomyelin, 2-oleoylglycerol, suberate, and sebacate, and decreased liver Por and skeletal muscle ANGPTL4 mRNA expression. These changes correlate with improved insulin sensitivity and increased beta-oxidation, suggesting MOTS-c modulates key metabolic pathways linked to obesity and type 2 diabetes.
Methods Used
Diet-induced obese mice were injected with MOTS-c (2.5 mg/kg twice daily) for 3 days. Plasma metabolites were analyzed using an unbiased metabolomics approach. Control group received water. Sample size: n=6 per group. Outcomes included plasma metabolite levels, mRNA expression, and glucose levels.
Main Finding
MOTS-c reduced plasma sphingosine 1-phosphate by 14% (P=0.022), palmitoyl sphingomyelin by 23% (P=0.0067), 2-oleoylglycerol by 32% (P=0.0281), suberate by 40% (P=0.0082), and sebacate by 42% (P=0.0464). It also reduced liver Por mRNA (P<0.05) and skeletal muscle ANGPTL4 mRNA (P<0.05). Blood glucose was significantly lower in MOTS-c group (P<0.05).
Confidence Level
Moderate. Study used a controlled animal model with clear group comparisons and reported p-values. However, sample size was small (n=6 per group), blinding and randomization not specified, and effect sizes not reported. Results are consistent with prior findings on MOTS-c and insulin sensitivity.
Study Flags
Red Flags
- •Small sample size (n=6 per group)
- •Blinding and randomization not specified
- •No effect sizes or confidence intervals reported
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
MOTS-c reduces multiple fat molecules linked to diabetes — not just one
Most treatments target one pathway, but MOTS-c simultaneously lowers 5 different fat-related metabolites across 3 metabolic pathways (sphingolipid, monoacylglycerol, dicarboxylate), which is rare and suggests broad metabolic reprogramming.
Practical Takeaways
Consider lifestyle changes that naturally boost MOTS-c, like exercise or fasting — since MOTS-c is an 'exercise mimetic'.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at mice that got a special peptide and saw that their blood sugar got better and some chemicals in their blood changed. But it doesn’t prove the peptide caused the change — it just shows they happened together. We can’t say it would work in people.
Strengths
- Used unbiased metabolomics platform (Metabolon)
- Statistical correction for multiple comparisons (q-values)
- Used appropriate controls (water-injected)
Weaknesses
- No randomization reported (classified as unknown → not RCT)
- No blinding reported (cannot assume it was done)
- No sample size justification
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave a special peptide called MOTS-c to fat mice and found it helped their bodies burn fat more efficiently and lowered blood sugar. It changed levels of certain fats and chemicals in the blood that are linked to diabetes and obesity.
Research results
MOTS-c lowered 5 key fat-related chemicals in blood by 14% to 42% (all p<0.05). It also reduced gene activity in liver and muscle linked to fat storage. Blood sugar dropped significantly (p<0.05).
What this means - more context
Results are from mice, not humans. While promising, human relevance is not confirmed. The changes are biologically significant in the mouse model but require human trials to assess real-world impact.
This study investigates the effects of MOTS-c on plasma metabolites and insulin sensitivity in diet-induced obese mice using an unbiased metabolomics approach.
MOTS-c injection in diet-induced obese mice significantly reduced plasma levels of sphingosine 1-phosphate, palmitoyl sphingomyelin, 2-oleoylglycerol, suberate, and sebacate, and decreased liver Por and skeletal muscle ANGPTL4 mRNA expression. These changes correlate with improved insulin sensitivity and increased beta-oxidation, suggesting MOTS-c modulates key metabolic pathways linked to obesity and type 2 diabetes.
Methods Used
Diet-induced obese mice were injected with MOTS-c (2.5 mg/kg twice daily) for 3 days. Plasma metabolites were analyzed using an unbiased metabolomics approach. Control group received water. Sample size: n=6 per group. Outcomes included plasma metabolite levels, mRNA expression, and glucose levels.
Main Finding
MOTS-c reduced plasma sphingosine 1-phosphate by 14% (P=0.022), palmitoyl sphingomyelin by 23% (P=0.0067), 2-oleoylglycerol by 32% (P=0.0281), suberate by 40% (P=0.0082), and sebacate by 42% (P=0.0464). It also reduced liver Por mRNA (P<0.05) and skeletal muscle ANGPTL4 mRNA (P<0.05). Blood glucose was significantly lower in MOTS-c group (P<0.05).
Confidence Level
Moderate. Study used a controlled animal model with clear group comparisons and reported p-values. However, sample size was small (n=6 per group), blinding and randomization not specified, and effect sizes not reported. Results are consistent with prior findings on MOTS-c and insulin sensitivity.
Study Flags
Red Flags
- •Small sample size (n=6 per group)
- •Blinding and randomization not specified
- •No effect sizes or confidence intervals reported
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
MOTS-c reduces multiple fat molecules linked to diabetes — not just one
Most treatments target one pathway, but MOTS-c simultaneously lowers 5 different fat-related metabolites across 3 metabolic pathways (sphingolipid, monoacylglycerol, dicarboxylate), which is rare and suggests broad metabolic reprogramming.
Practical Takeaways
Consider lifestyle changes that naturally boost MOTS-c, like exercise or fasting — since MOTS-c is an 'exercise mimetic'.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at mice that got a special peptide and saw that their blood sugar got better and some chemicals in their blood changed. But it doesn’t prove the peptide caused the change — it just shows they happened together. We can’t say it would work in people.
Strengths
- Used unbiased metabolomics platform (Metabolon)
- Statistical correction for multiple comparisons (q-values)
- Used appropriate controls (water-injected)
Weaknesses
- No randomization reported (classified as unknown → not RCT)
- No blinding reported (cannot assume it was done)
- No sample size justification
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study did a good job measuring many things in the mice’s blood, but they didn’t randomly give the peptide or hide who got it — so we can’t be sure the results weren’t just luck or something else. That makes the results less trustworthy for real-world use.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
19 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 58 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Study is in mice, not humans; no randomization or blinding reported (classified as unknown, so not RCT); cannot prove MOTS-c causes improved insulin sensitivity in humans.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
8 researchersIf this is your work, this is how we attribute it on Fit Body Science. Su‐Jeong Kim is listed as the lead author.